
Eagle Pharmaceuticals, Inc. – NASDAQ:EGRX
Eagle Pharmaceuticals stock price today
Eagle Pharmaceuticals stock price monthly change
Eagle Pharmaceuticals stock price quarterly change
Eagle Pharmaceuticals stock price yearly change
Eagle Pharmaceuticals key metrics
Market Cap | 7.12M |
Enterprise value | 415.45M |
P/E | 10.67 |
EV/Sales | 1.31 |
EV/EBITDA | 5.74 |
Price/Sales | 1.28 |
Price/Book | 1.74 |
PEG ratio | 0.02 |
EPS | 1.19 |
Revenue | 257.55M |
EBITDA | 39.32M |
Income | 15.56M |
Revenue Q/Q | -12.80% |
Revenue Y/Y | -5.37% |
Profit margin | 11.26% |
Oper. margin | 25.57% |
Gross margin | 70.01% |
EBIT margin | 25.57% |
EBITDA margin | 15.27% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEagle Pharmaceuticals stock price history
Eagle Pharmaceuticals stock forecast
Eagle Pharmaceuticals financial statements
Sep 2022 | 65.90M | -3.51M | -5.33% |
---|---|---|---|
Dec 2022 | 60.69M | 8.16M | 13.45% |
Mar 2023 | 66.30M | 5.75M | 8.67% |
Jun 2023 | 64.64M | 5.16M | 7.99% |
Sep 2022 | 390067000 | 154.66M | 39.65% |
---|---|---|---|
Dec 2022 | 406160000 | 172.6M | 42.5% |
Mar 2023 | 414175000 | 171.33M | 41.37% |
Jun 2023 | 404822000 | 152.78M | 37.74% |
Sep 2022 | -13.23M | -11.23M | 3.29M |
---|---|---|---|
Dec 2022 | 37.55M | -9K | 2.38M |
Mar 2023 | -33.51M | -12.55M | 12.64M |
Jun 2023 | -126K | -6K | -6.41M |
Eagle Pharmaceuticals alternative data
Aug 2023 | 134 |
---|---|
Sep 2023 | 134 |
Oct 2023 | 134 |
Nov 2023 | 134 |
Dec 2023 | 134 |
Jan 2024 | 134 |
Feb 2024 | 134 |
Mar 2024 | 134 |
Apr 2024 | 134 |
May 2024 | 134 |
Jun 2024 | 134 |
Jul 2024 | 134 |
Eagle Pharmaceuticals other data
Period | Buy | Sel |
---|---|---|
May 2023 | 0 | 60000 |
Oct 2023 | 0 | 20245 |
Nov 2023 | 0 | 21619 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | TARRIFF SCOTT director, 10 perc.. | Common Stock | 10,694 | $13.87 | $148,326 | ||
Sale | TARRIFF SCOTT director, 10 perc.. | Common Stock | 10,925 | $13.82 | $150,984 | ||
Option | GRAVES MICHAEL director | Common Stock | 9,360 | $4.94 | $46,238 | ||
Option | GRAVES MICHAEL director | Stock Option (right to buy) | 9,360 | $4.94 | $46,238 | ||
Sale | TARRIFF SCOTT director, 10 perc.. | Common Stock | 710 | $15.11 | $10,728 | ||
Sale | TARRIFF SCOTT director, 10 perc.. | Common Stock | 10,024 | $14.41 | $144,446 | ||
Sale | TARRIFF SCOTT director, 10 perc.. | Common Stock | 9,511 | $15.23 | $144,853 | ||
Sale | TARRIFF SCOTT director, 10 perc.. | Common Stock | 15,000 | $19.98 | $299,700 | ||
Sale | TARRIFF SCOTT director, 10 perc.. | Common Stock | 14,800 | $21.06 | $311,688 | ||
Sale | TARRIFF SCOTT director, 10 perc.. | Common Stock | 200 | $21.52 | $4,304 |
Patent |
---|
Application Filling date: 10 May 2022 Issue date: 25 Aug 2022 |
Application Filling date: 2 Dec 2021 Issue date: 24 Mar 2022 |
Application Filling date: 18 Nov 2021 Issue date: 10 Mar 2022 |
Application Filling date: 26 Aug 2021 Issue date: 23 Dec 2021 |
Grant Utility: Fulvestrant formulations Filling date: 8 Apr 2013 Issue date: 23 Nov 2021 |
Application Filling date: 19 Jul 2021 Issue date: 11 Nov 2021 |
Grant Utility: Formulations of bendamustine Filling date: 12 Jul 2019 Issue date: 31 Aug 2021 |
Application Filling date: 16 Sep 2020 Issue date: 26 Aug 2021 |
Application Filling date: 21 May 2019 Issue date: 5 Aug 2021 |
Application Filling date: 8 May 2020 Issue date: 15 Apr 2021 |
Quarter | Transcript |
---|---|
Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Q1 2023 9 May 2023 | Q1 2023 Earnings Call Transcript |
Q4 2022 13 Mar 2023 | Q4 2022 Earnings Call Transcript |
Q3 2022 7 Nov 2022 | Q3 2022 Earnings Call Transcript |
Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year
Endo: A Win In California But Equity Value Still A Question
Endo International: Loses Vasostrict Trial
Endo International: Hires Restructuring Advisor
Endo International: All About Ongoing Litigation
Eagle Pharmaceuticals: A Potential Reopening Play
-
What's the price of Eagle Pharmaceuticals stock today?
One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $3.18.
-
When is Eagle Pharmaceuticals's next earnings date?
Unfortunately, Eagle Pharmaceuticals's (EGRX) next earnings date is currently unknown.
-
Does Eagle Pharmaceuticals pay dividends?
No, Eagle Pharmaceuticals does not pay dividends.
-
How much money does Eagle Pharmaceuticals make?
Eagle Pharmaceuticals has a market capitalization of 7.12M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 84.56% to 316.61M US dollars.
-
What is Eagle Pharmaceuticals's stock symbol?
Eagle Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "EGRX".
-
What is Eagle Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
-
How do i buy shares of Eagle Pharmaceuticals?
Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Eagle Pharmaceuticals's key executives?
Eagle Pharmaceuticals's management team includes the following people:
- Mr. Scott L. Tarriff Founder, Pres, Chief Executive Officer & Director(age: 65, pay: $1,400,000)
- Mr. David M. Pernock Executive Vice President of Operations(age: 72, pay: $896,320)
- Mr. Brian Joseph Cahill Chief Financial Officer(age: 56, pay: $500,240)
-
Is Eagle Pharmaceuticals founder-led company?
Yes, Eagle Pharmaceuticals is a company led by its founder Mr. Scott L. Tarriff.
-
How many employees does Eagle Pharmaceuticals have?
As Jul 2024, Eagle Pharmaceuticals employs 134 workers.
-
When Eagle Pharmaceuticals went public?
Eagle Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 12 Feb 2014.
-
What is Eagle Pharmaceuticals's official website?
The official website for Eagle Pharmaceuticals is eagleus.com.
-
Where are Eagle Pharmaceuticals's headquarters?
Eagle Pharmaceuticals is headquartered at 50 Tice Boulevard, Woodcliff Lake, NJ.
-
How can i contact Eagle Pharmaceuticals?
Eagle Pharmaceuticals's mailing address is 50 Tice Boulevard, Woodcliff Lake, NJ and company can be reached via phone at +20 13 265300.
Eagle Pharmaceuticals company profile:

Eagle Pharmaceuticals, Inc.
eagleus.comNASDAQ
134
Drug Manufacturers - Specialty & Generic
Healthcare
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Woodcliff Lake, NJ 07677
CIK: 0000827871
ISIN: US2697961082
CUSIP: 269796108